Source: Health Products Regulatory Authority (IE) Revision Year: 2021 Publisher: Accord Healthcare Ireland Ltd., Euro House, Euro Business Park, Little Island, Cork T45 K857, Ireland
Pantoflux 40 mg gastro-resistant tablets.
| Pharmaceutical Form |
|---|
|
Gastro-resistant tablet. Elliptical, biconvex, dark yellow gastro-resistant tablet. |
Each gastro-resistant tablet contains 40 mg of pantoprazole (as 45.16 mg pantoprazole sodium sesquihydrate).
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Pantoprazole |
Pantoprazole is a substituted benzimidazole which inhibits the secretion of hydrochloric acid in the stomach by specific blockade of the proton pumps of the parietal cells. |
| List of Excipients |
|---|
|
Tablet core: Mannitol Sub coating: Opadry white OY-D-7233; consisting of: Enteric coating: Kollicoat MAE 30 DP, yellow; consisting of: |
Aluminium/aluminium blister pack.
Tablet container (HDPE) closed with PP cap with integrated desiccant.
Pack sizes:
Blister: 7, 14, 15, 20, 28, 30, 56, 60, 98, 100 tablets and 10 × 14 tablets (hospital pack)
Tablet container: 30, 100, 250 tablets.
Not all pack sizes may be marketed.
Accord Healthcare Ireland Ltd., Euro House, Euro Business Park, Little Island, Cork T45 K857, Ireland
PA2315/187/002
Date of First Authorisation: 9th June 2008
Date of last renewal: 3rd May 2013
| Drug | Countries | |
|---|---|---|
| PANTOFLUX | Cyprus, Ireland |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
